Kadence Bio is developing its lead asset KH-001 as the first FDA-approved treatment for premature ejaculation (PE), and a pipeline of compounds to target mood disorders.
Our development programs
Our Lead asset: KH-001
Kadence Bio is developing a small molecule, KH-001, as an on-demand orally-administered treatment for premature ejaculation.
Premature ejaculation (PE) is a distressing condition in which patients ejaculate too quickly before or shortly after penetration (often within one minute). There are currently no treatments approved by the FDA, despite the condition affecting up to 20% of men. These men report lower levels of sexual functioning and satisfaction, decreased self-esteem, and higher levels of personal distress. Partners of these men also suffer, and report sexual dissatisfaction and frustration, as well as problems in the relationship.
KH-001 has shown promising results in proof-of-concept animal studies and a Phase 1 first-in-human clinical study which completed dosing in Q3 2024. A first efficacy proof-of-concept study is planned to be initiated in 2025. If you are a male affected by premature ejaculation aged between 18 and 64 and interested in participating in our trial, please contact: info@kadencebio.com.
Pipeline Program
We are developing proprietary new chemical entities (NCEs) whose pharmacological and pharmacokinetic properties can be fine-tuned to target a range of neuropsychiatric disorders with high unmet needs.
The Phase 1 first-in-human clinical trial for KH-001 for use in premature ejaculation completed in Q4 2024.
